Bausch Health Companies Inc. Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
Bausch Health Companies Inc. (BHC) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of -$11.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2017-03-01
- Bausch Health Companies Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- Bausch Health Companies Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2016-03-31 was -$1.40M, a 107.82% decline year-over-year.
- Bausch Health Companies Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2015-12-31 was -$109.70M.
- Bausch Health Companies Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2015-09-30 was -$3.90M.
- Bausch Health Companies Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2016 was -$11.00M.
- Bausch Health Companies Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2015 was -$88.00M.
- Bausch Health Companies Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2014 was -$44.00M.
- Bausch Health Companies Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2013 was -$46.60M.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 3 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 3 month as first filed | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 6 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 6 month as first filed | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 9 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 9 month as first filed | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | -$11.00M 10-K · filed 2017-03-01 | |||||||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$1.40M 10-Q · filed 2016-08-09 | -$111.10M derived: sum of 3 quarters · filed 2017-03-01 | -$115.00M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2016-03-31 | -$1.40M 10-Q · filed 2016-06-07 | -$111.10M derived: sum of 2 quarters · filed 2017-03-01 | -$115.00M derived: sum of 3 quarters · filed 2017-03-01 | -$107.30M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-12-31 | -$109.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$113.60M derived: sum of 2 quarters · filed 2017-03-01 | -$105.90M derived: sum of 3 quarters · filed 2017-03-01 | -$88.00M 10-K · filed 2017-03-01 | ||||
| 2015-09-30 | -$3.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $3.80M derived: sum of 2 quarters · filed 2016-11-09 | $21.70M 10-Q · filed 2016-11-09 | -$85.80M 10-Q · filed 2015-10-26 | $16.20M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $7.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $25.60M 10-Q · filed 2016-08-09 | -$61.50M 10-Q · filed 2015-07-28 | $20.10M derived: sum of 3 quarters · filed 2017-03-01 | $18.10M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $17.90M 10-Q · filed 2016-06-07 | -$21.20M 10-Q · filed 2015-04-30 | $12.40M derived: sum of 2 quarters · filed 2017-03-01 | $10.40M derived: sum of 3 quarters · filed 2017-03-01 | $1.60M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | -$5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$7.50M derived: sum of 2 quarters · filed 2017-03-01 | -$16.30M derived: sum of 3 quarters · filed 2017-03-01 | -$44.00M 10-K · filed 2017-03-01 | -$44.10M 10-K · filed 2015-02-25 | |||
| 2014-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-26 | -$10.80M derived: sum of 2 quarters · filed 2015-10-26 | -$38.50M 10-Q · filed 2015-10-26 | -$49.20M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2014-06-30 | -$8.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | -$36.50M 10-Q · filed 2015-07-28 | -$47.20M derived: sum of 3 quarters · filed 2016-04-29 | -$61.60M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2014-03-31 | -$27.70M 10-Q · filed 2015-04-30 | -$38.40M derived: sum of 2 quarters · filed 2016-04-29 | -$52.80M derived: sum of 3 quarters · filed 2016-04-29 | -$67.50M derived: sum of 4 quarters · filed 2016-04-29 | ||||
| 2013-12-31 | -$10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | -$25.10M derived: sum of 2 quarters · filed 2016-04-29 | -$39.80M derived: sum of 3 quarters · filed 2016-04-29 | -$46.60M 10-K · filed 2016-04-29 | -$46.59M 10-K · filed 2014-02-28 | |||
| 2013-09-30 | -$14.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-24 | -$29.10M derived: sum of 2 quarters · filed 2014-10-24 | -$35.90M 10-Q · filed 2014-10-24 | -$35.92M 10-Q · filed 2013-11-01 | -$45.89M derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2013-06-30 | -$14.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | -$21.50M 10-Q · filed 2014-08-01 | -$21.53M 10-Q · filed 2013-08-07 | -$31.49M derived: sum of 3 quarters · filed 2015-02-25 | -$38.87M derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2013-03-31 | -$6.80M 10-Q · filed 2014-05-09 | -$6.85M 10-Q · filed 2013-05-03 | -$16.79M derived: sum of 2 quarters · filed 2015-02-25 | -$24.17M derived: sum of 3 quarters · filed 2015-02-25 | -$34.08M derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2012-12-31 | -$9.99M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | -$17.37M derived: sum of 2 quarters · filed 2015-02-25 | -$27.28M derived: sum of 3 quarters · filed 2015-02-25 | -$31.10M 10-K · filed 2015-02-25 | -$31.07M 10-K · filed 2013-02-28 | |||
| 2012-09-30 | -$7.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | -$17.29M derived: sum of 2 quarters · filed 2013-11-01 | -$21.11M 10-Q · filed 2013-11-01 | -$1.66M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-06-30 | -$9.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | -$13.73M 10-Q · filed 2013-08-07 | $5.72M derived: sum of 3 quarters · filed 2014-02-28 | $3.24M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-03-31 | -$3.82M 10-Q · filed 2013-05-03 | $15.63M derived: sum of 2 quarters · filed 2014-02-28 | $13.15M derived: sum of 3 quarters · filed 2014-02-28 | -$2.05M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2011-12-31 | $19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $16.98M derived: sum of 2 quarters · filed 2014-02-28 | $1.78M derived: sum of 3 quarters · filed 2014-02-28 | -$37.70M 10-K · filed 2014-02-28 | ||||
| 2011-09-30 | -$2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | -$17.68M derived: sum of 2 quarters · filed 2012-11-05 | -$57.16M 10-Q · filed 2012-11-05 | |||||
| 2011-06-30 | -$15.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | -$54.68M 10-Q · filed 2012-08-03 | ||||||
| 2011-03-31 | -$39.48M 10-Q · filed 2012-05-04 | |||||||
| 2010-12-31 | -$14.48M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |